entertainment -WSS

entertainment

author：knowledge 2025-09-06 04:42:09 - browse：86939

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Texas board proposes rules on abortion law emergency exemption

focus

hotspot

WSS

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Pregnancy ages women, but effects reverse after delivery

Clinical trials giant ICON acquires HumanFirst

Steward Health Care expansion into Malta flopped

Clinical trials giant ICON acquires HumanFirst

Mirador, a new biotech startup, launches with $400 million

knowledge

entertainment

focus

Alkermes shareholders re

Testing GLP

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Peter Hotez and the public health issue of online harassment

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Peter Hotez and the public health issue of online harassment

U.K. officials, researchers try to ease path for bespoke genetic treatments

Bright Health sells Medicare Advantage business to Molina

How to fix the rural physician shortage in the U.S.

explore

CRISPR technology availability, affordability needs to be expanded

Change Healthcare cyberattack outage could last weeks

Obesity now affects over 1 billion people worldwide, study finds

Pfizer, Moderna say biotech, pharma drug development is a sprint

In search for therapies for solid tumors, companies turn to claudin

Yancopoulos of Regeneron works to expand Dupixent success

focus

hotspot

hotspot

explore